Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers
(07/23/2008)
Researchers recommend that at least 15 lymph nodes be removed and examined in patients with early gastric or pancreatic cancers. These results were recently published in the Archives of Surgery.
Gemzar® Improves Survival with Early Pancreatic Cancer
(06/10/2008)
Adjuvant (post-surgery) chemotherapy with Gemzar® (gemcitabine) significantly improves disease-free and overall survival among patients with early pancreatic cancer. These findings were presented at the 2008 annual meeting of the American Society of Clinical Oncology.
Abraxane®/Gemzar® Promising in Pancreatic Cancer
(04/17/2008)
The chemotherapy combination consisting of Abraxane® (paclitaxel) and Gemzar® (gemcitabine) appears promising for the treatment of advanced pancreatic cancer. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research.
Addition of Erbitux® Does Not Improve Outcomes in Pancreatic Cancer
(04/08/2008)
The addition of the targeted agent Erbitux® (cetuximab) to the chemotherapy combination Gemzar® (gemcitabine) and Platinol® (cisplatin) does not improve outcomes compared with chemotherapy only in advanced pancreatic cancer. These results were recently published in Lancet Oncology.
Addition of Gemzar® in Early Pancreatic Cancer May Modestly Improve Survival
(03/05/2008)
The addition of Gemzar® (gemcitabine) to 5-fluorouracil may modestly improve survival among patients with early pancreatic cancer. Further study is necessary, however, to determine the true benefit of Gemzar in early pancreatic cancer. These results were published in the Journal of the American Medical Association.
More...
Screening/Prevention
Being Overweight Associated with Increased Risk of Several Cancers
(02/19/2008)
Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet.
Flavonols May Reduce Risk of Pancreatic Cancer in Smokers
(10/11/2007)
According to the results of a study published in the American Journal of Epidemiology, higher dietary intake of flavonols (compounds found in many plant foods) may reduce the risk of pancreatic cancer, particularly among smokers. These results were previously presented at the 2007 annual meeting of the American Association for Cancer Research.
Optical Markers Offer Promise for Earlier Detection of Pancreatic Cancer
(08/28/2007)
According to the results of a study published in Clinical Cancer Research, evaluation of how light scatters off of tissue adjacent to the pancreas may help to identify pancreatic cancer at an earlier stage.
Snus Increases Risk of Pancreatic Cancer
(06/21/2007)
According to an article recently published in The Lancet, Scandinavian moist snuff (snus) increases the risk of developing pancreatic cancer. However, it has not been confirmed that snus increases the risk of oral or lung cancer.
miRNA Expression Can Help Diagnose Pancreatic Cancer
(05/02/2007)
According to an article published in the Journal of the American Medical Association, microRNA (miRNA) expression patterns can help to distinguish between pancreatic cancer and pancreatitis, ultimately improving the accuracy of diagnosing pancreatic cancer.
More...
Stages I-III
Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers
(07/23/2008)
Researchers recommend that at least 15 lymph nodes be removed and examined in patients with early gastric or pancreatic cancers. These results were recently published in the Archives of Surgery.
Gemzar® Improves Survival with Early Pancreatic Cancer
(06/10/2008)
Adjuvant (post-surgery) chemotherapy with Gemzar® (gemcitabine) significantly improves disease-free and overall survival among patients with early pancreatic cancer. These findings were presented at the 2008 annual meeting of the American Society of Clinical Oncology.
Abraxane®/Gemzar® Promising in Pancreatic Cancer
(04/17/2008)
The chemotherapy combination consisting of Abraxane® (paclitaxel) and Gemzar® (gemcitabine) appears promising for the treatment of advanced pancreatic cancer. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research.
Addition of Gemzar® in Early Pancreatic Cancer May Modestly Improve Survival
(03/05/2008)
The addition of Gemzar® (gemcitabine) to 5-fluorouracil may modestly improve survival among patients with early pancreatic cancer. Further study is necessary, however, to determine the true benefit of Gemzar in early pancreatic cancer. These results were published in the Journal of the American Medical Association.
Radiation Therapy May Be Effective in Early Pancreatic Cancer
(02/11/2008)
Radiation therapy may improve survival among patients diagnosed with early-stage pancreatic cancer. These findings were recently published in the journal Cancer.
More...
Stage IV
Abraxane®/Gemzar® Promising in Pancreatic Cancer
(04/17/2008)
The chemotherapy combination consisting of Abraxane® (paclitaxel) and Gemzar® (gemcitabine) appears promising for the treatment of advanced pancreatic cancer. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research.
Addition of Erbitux® Does Not Improve Outcomes in Pancreatic Cancer
(04/08/2008)
The addition of the targeted agent Erbitux® (cetuximab) to the chemotherapy combination Gemzar® (gemcitabine) and Platinol® (cisplatin) does not improve outcomes compared with chemotherapy only in advanced pancreatic cancer. These results were recently published in Lancet Oncology.
Levels of CA 19-9 Following Treatment Not Indicative of Survival in Pancreatic Cancer
(02/08/2008)
Among patients with pancreatic cancer, levels of a specific component of certain carbohydrates (CA19-9) during and following treatment are not associated with survival outcomes. These results were recently published in The Lancet Oncology.
NCCN Updates Pancreatic Cancer Guidelines
(12/12/2007)
The National Comprehensive Cancer Network (NCCN), an alliance of 21 leading cancer centers, has updated its guidelines regarding the care of pancreatic cancer patients. The updated guidelines include a new section on supportive care and a greater emphasis on use of neoadjuvant (before surgery) therapy for patients with cancers that are borderline resectable (cancers that can possibly be surgically removed, but that run a risk of incomplete removal).
Different Chemotherapy Combinations Effective in Pancreatic Cancer
(11/09/2007)
According to an article recently published in Annals of Oncology, different chemotherapy regimens may be similarly effective in the treatment of advanced pancreatic cancer but produce varying side effects.
More...
Recurrent
NCCN Updates Pancreatic Cancer Guidelines
(12/12/2007)
The National Comprehensive Cancer Network (NCCN), an alliance of 21 leading cancer centers, has updated its guidelines regarding the care of pancreatic cancer patients. The updated guidelines include a new section on supportive care and a greater emphasis on use of neoadjuvant (before surgery) therapy for patients with cancers that are borderline resectable (cancers that can possibly be surgically removed, but that run a risk of incomplete removal).
GEMOX Active in Recurrent Pancreatic Cancer
(02/24/2006)
According to a an article recently published in the British Journal of Cancer, the chemotherapy combination consisting of Gemzar® (gemcitabine) plus Eloxatin® (oxaliplatin), referred to as GEMOX, has activity in the treatment of pancreatic cancer that has stopped responding to Gemzar.
Pancreatic Cancer Research Map Will Track Researchers, Studies and Funding Opportunities
(05/10/2005)
The Pancreatic Cancer Research Map was first launched during Pancreatic Cancer Awareness Month in November 2004. The second phase has begun with the addition of grants from PanCAN and the Lustgarten Foundation.
Further Evidence that Rubitecan Offers Benefit for Refractory Pancreatic Cancer
(12/01/2003)
According to results presented at the Chemotherapy Foundation Symposium XXI, the anticancer agent rubitecan (Orathecin™) appears to provide a treatment alternative to patients with recurrent pancreatic cancer.
Raltitrexed and Camptosar® Effective in Recurrent Pancreatic Cancer
(04/27/2003)
According to an article recently published in the
British Journal of Cancer, Camptosar® plus raltitrexed demonstrates anti-cancer activity inpatients with advanced pancreatic cancer that has stopped responding to Gemzar®.
More...